I am a
Home I AM A Search Login

Papers of the Week


Papers: 2 Sep 2023 - 8 Sep 2023

RESEARCH TYPE:
Review


Pharmacology/Drug Development

PAIN TYPE:
Inflammation/Inflammatory, Itch


2023 Sep 05


Immunotherapy


37667972

Abrocitinib for the treatment of atopic dermatitis.

Authors

Lé AM, Gooderham M, Torres T

Abstract

Abrocitinib is an oral small molecule which selectively inhibits JAK1, modulating multiple cytokine pathways involved in atopic dermatitis. Both abrocitinib 200 mg and 100 mg reached efficacy results comparable to dupilumab and superior to placebo. Abrocitinib 200 mg was superior to dupilumab in some trials, consistently providing a faster response and itch relief from week 2 to 26. Continuous abrocitinib 200 mg is the most effective at controlling this disease, but with an induction-maintenance approach with abrocitinib 200 mg followed by 100 mg, over 55% of patients did not flare for 40 weeks. Abrocitinib common adverse effects are nonserious. A self-limited dose-related decrease in platelet counts was consistently observed, without clinical repercussion. Abrocitinib demonstrated high efficacy and a favorable safety profile.